Repeated Measurement of the Novel Atrial Biomarker BMP10 (Bone Morphogenetic Protein 10) Refines Risk Stratification in Anticoagulated Patients With Atrial Fibrillation: Insights From the ARISTOTLE Trial.
Konstantinos I GkarmirisJohan LindbäckJohn H AlexanderChristopher B GrangerPeter KastnerRenato Deláscio LopesAndré ZieglerJonas OldgrenAgneta SiegbahnLars WallentinZiad HijaziPublished in: Journal of the American Heart Association (2024)
Elevated levels of BMP10 at 2 months strengthened the associations with the risk of ischemic stroke, hospitalization for heart failure, and all-cause mortality. Repeated measurements of BMP10 may further refine risk stratification in patients with AF.